BRUPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of BRUPHARMA is 3.1% (moderate). The 2024 annual accounts show negative equity (-€46,276) and a net result of €23,906. Equity is growing by about 20% per year across the filed financial years. Its solvency ranks better than 9% of 9,537 sector peers (NACE 47, financial year 2024). The company has been active since 1997 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
11-01
Gazette deed
Resignation: TWEE-DE (director)Appointment: TWEE-DE (niet statutaire enige bestuurder) · Amendment of the articles · Capital9 facts ▸
- General meeting, “buitengewone algemene vergadering, eenparigheid van stemmen” (deed in Dutch)
- Amendment of the articles (2 times)
- Capital, €61,973.38
- Power of attorney, Mireille BEDERT
- Power of attorney, David VAN LIERDE
- Director resignation, TWEE-DE (director)
- Director appointment, TWEE-DE (niet statutaire enige bestuurder)
- Registered office clause, “1083 Ganshoren, Margaretha Van Oostenrijkplein 3” (deed in Dutch)
- Other provision, “brupharma@telenet.be, geen website” (deed in Dutch)
Show earlier events
About the unread acts
Of the 5 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.